Sunday, January 24, 2021

Vaccine Update: Serum Institute Completes Enrolment For Phase 3 Trials Of Oxford Covid-19 Vaccine

Must Read

Early Cryptopunk Digital Collectible Ether sells for $ 762K – Coindesk

Some early pixel art has just been sold 605 ETH, Or purchased 1 761,889.FlemingdooA decentralized autonomous body (DAO)...

Bitcoin ETF – Valkyrie Digital Asset Files for Coindesk

Valkiri has filed a digital asset Application Friday is the second such filing in the last 30 days...

Behind Bitcoin Core Lead Maintenance Steps, Encourages Decentralization – Coindesk

Vladimir van der Laan, the Bitcoin Core's top maintainer, has decided to take a "more" background role in...



New Delhi: The Pune-based pharmaceutical company Serum Institute of India & Indian Council of Medical Research (ICMR) has announced the completion of enrollment for Phase 3 trials of the British-Swedish pharma major AstraZeneca and Oxford University Covid-19 vaccine candidate named Covishield. A report by Mint says that the trials will be conducted at 15 different centers across the country.

ALSO READ: Will Pfizer’s Covid-19 Vaccine Become Available In India Soon? Know All About It

On Wednesday, the CEO Adar Poonawalla, said that if the approvals from regulatory bodies are in place and in time a vaccine against the coronavirus disease (Covid-19) is likely to be available in the country by January 2021.

“Based on the success of the trials in India and the United Kingdom, and if approvals from regulatory bodies are in place in time, then we can expect the vaccine to be available in India by January 2021, only if it’s proven immunogenic and efficacious, “Poonawalla told the media.

Serum Institute will provide the vaccine for low-and-middle-income countries. The vaccine shot has so far been given to thousands of people in India and abroad with no safety concerns Poonawalla said and it will take around two to three years to ascertain the long-term effects of the vaccine, he further added. According to a report published in the British medical journal The Lancet, the potential Covid-19 vaccine produced a dual immune response in people aged 18 to 55. AstraZeneca and Oxford University have said a two-dose regimen showed greater promise, while a single- dose injection is also being tested in trials.

.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News

Early Cryptopunk Digital Collectible Ether sells for $ 762K – Coindesk

Some early pixel art has just been sold 605 ETH, Or purchased 1 761,889.FlemingdooA decentralized autonomous body (DAO)...

Bitcoin ETF – Valkyrie Digital Asset Files for Coindesk

Valkiri has filed a digital asset Application Friday is the second such filing in the last 30 days for the Bitcoin Exchange-Trade Fund...

Behind Bitcoin Core Lead Maintenance Steps, Encourages Decentralization – Coindesk

Vladimir van der Laan, the Bitcoin Core's top maintainer, has decided to take a "more" background role in the interests of further decentralization...

Money reconsideration: Letter to President Biden – Kindesk

Welcome to re-imagine this week's money, you have two days to be the new president of the United States. Meanwhile, with various executive...

SEC calls suspicious crypto companies targeting global traders – Kindesk

The U.S. government’s top investment surveillance has flagged a series of registered cryptocurrency firms to deceive most international investors with fake corporate information.Of...

More Articles Like This